| Hint | Answer |
|---|
| When using Enoxaparin, anti-Xa should be monitored if the patient is _____, pregnant, or has renal insufficiency. | |
| Toxic monitoring parameters of Enoxaparin include: ____ and signs of bleeding. | |
| Brand Name Lepirudin | |
| Fondaparinux works through anti-___a activity only. | |
| Brand Name Warfarin | |
| Treatment dose of Fondaparinux for a patient weighing > 100kg is: ___mg | |
| T or F: Enoxaparin requires dose adjustment in renal impairment. | |
| UFH toxic monitoring includes: bleeding complications and ___ every other day x 2 weeks or until stopped | |
| Phytonadione Brand Name | |
| Normal prothrombin time is __-__ seconds (enter as # - #) | |
| Dabigatran is indicated for: ____ ____ | |
| Warfarin dosing is: initiate __mg PO after UFH or LMWH initiated. | |
| Treatment dose of Fondaparinux for a patient < 50kg is: ___mg | |
| Dabigatran dosing is: ___mg PO BID. | |
| Fondaparinux prophylactic dosing is: ___mg SQ every 24 hours | |
| T or F: Fondaparinux treatment dosing is weight based. | |
| Fondaparinux monitoring may include: ___ | |
| T or F: Fondaparinux administration might produce injection site reactions. | |
| UFH target patients include all except: (a) immobile (b) post-op (c) trauma (d) spinal cord injuries (e) all of the above are target patients. | |
| Lepirudin, Argatroban, and Dabigatran all work by directly inhibiting _______. | |
| The goal aPTT for UFH therapy is ___-___. (enter as # - #) | |
| Warfarin inhibits vitamin K _______ reductase. | |
| UFH prophylactic dosing is: _____ units SQ every 8-12 hours. | |
| | Hint | Answer |
|---|
| Heparin's antidote | |
| Side effects of Dabigatran are bleeding and _________. | |
| UFH treatment dosing is: ___units/kg bolus followed by 18 units/kg/hour. | |
| Lepirudin is indicated for ____ treatment in HIT patients. | |
| Dabigatran dosing in renal impairment (CrCl 15-30mL/min) is ___mg PO BID | |
| Side effects of UFH therapy include: bleeding, _________, HIT I, HIT II, and osteopenia. | |
| T or F: Warfarin is approved for prophylaxis & treatment of DVT/PE, acute MI, prosthetic heart valves, atrial fibrillation, and inherited clotting disorders. | |
| Brand Name Dabigatran | |
| UFH works by binding to ______, converting it from a slow inhibitor to a rapid inhibitor of thrombin. | |
| T or F: Patient education regarding enoxaparin should include teaching the patient how to inject the drug. | |
| Brand Name Fondaparinux | |
| UFH inactivates factors: ___ (most), X, IX, XI, and XII. | |
| T or F: If a patient experiences HIT I on UFH therapy, stop the treatment stat. | |
| Warfarin also interferes with endogenous anticoagulant proteins ___ & S. | |
| T or F: Enoxaparin inhibits factor II more than factor X. | |
| T or F: Fondaparinux has more thrombocytopenia than LMWH. | |
| Monitoring parameters of Warfarin are: prothrombin time and ____ | |
| T or F: Direct thrombin inhibitors have a reversal agent. | |
| Treatment dose of Fondaparinux for a patient weighing 50-100kg is: ___mg | |
| Argatroban is indicated for HIT or ____ | |
| UFH therapeutic monitoring for treatment doses includes: ___ | |
| Warfarin's S-isomer is metabolized by CYP450 ___. | |
| Brand Name Enoxaparin | |
| | Hint | Answer |
|---|
| Enoxaparin is indicated for the treatment & prophylaxis of DVT/PE and acute MI/_____ angina. | |
| Enoxaparin's starting PROPHYLACTIC dose is: ___mg SQ BID or 40mg SQ daily. | |
| Enoxaparin works by enhancing the activity of _____. | |
| T or F: UFH treatment doses are given as a continuous IV. | |
| T or F: If a patient experiences HIT II on UFH therapy, stop treatment immediately. | |
| T or F: Argatroban is given as a continuous IV infusion and requires dose adjustment for hepatic impairment. | |
| Normal INR is __-__ (enter as # - #) | |
| When on Lepirudin, ____ should be monitored every 4 hours until stable. | |
| Warfarin interferes with clotting factors: ___, ___, ___, and ___. (enter in order of longest to shortest time; separate answers by commas)) | |
| Fondaparinux is used for prophylaxis & treatment of DVT/PE, ACS, and ___ (not FDA approved) | |
| Warfarin's R-isomer is metabolized by CYP450 3A4 & ___ | |
| Lepirudin's dose is given as a ______ infusion. | |
| T or F: Phytonadione (Vitamin K analog) is an antidote to warfarin. | |
| Enoxaparin's starting TREATMENT dose is: ___mg/kg SQ BID or 1.5mg/kg daily. | |
| Possible side effects of Warfarin include: bleeding, ____ necrosis, and purple toe syndrome. | |
| T or F: 2C9 & 3A4 inhibitors and decreased vitamin K DECREASE the effect of warfarin. | |
| Brand Name UFH | |
| Some side effects of Enoxaparin include: bleeding, thrombocytopenia, and ____ at the injection site. | |
| T or F: Possible drug interactions with Dabigatran include p-glycoprotein inhibitors or inducers, e.g. PPIs and antacids. | |
| T or F: Cholestyramine interferes with warfarin absorption. | |
| T or F: UFH therapeutic uses include: prophylaxis & treatment of DVT/PE, acute coronary syndromes, and atrial fibrillation. | |
| Warfarin works by interfering with _______ synthesis of vitamin K dependent clotting factors. | |
| Argatroban might cause a false elevation in INR of __-__ points. (enter as # - #) | |
|
